CLINICAL TRIALS PROFILE FOR LESCOL XL

All Clinical Trials for LESCOL XL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00421005 ↗	Fluvastatin After Heart Transplantation	Unknown status	University of Bologna	Phase 4	2004-11-01	Statin therapy is a treatment with a proven positive impact on survival after heart transplantation. However, it is unclear whether the beneficial effect of this class of drugs depends solely on their LDL-lowering properties or on anti-inflammatory and immuno-modulatory properties. Thus, this study was designed to compare safety and efficacy of two different strategies: 1. high fixed statin dose vs. 2. low starting dose with LDL-driven doses adjustments.
NCT00487318 ↗	Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin	Completed	US Department of Veterans Affairs	Phase 2	2007-06-01	Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.
NCT00487318 ↗	Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin	Completed	VA Office of Research and Development	Phase 2	2007-06-01	Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.
NCT00487318 ↗	Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin	Completed	Bader, Ted, M.D.	Phase 2	2007-06-01	Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.

Clinical Trial Conditions for LESCOL XL

Condition Name

Condition Name for LESCOL XL
Intervention	Trials
Hypercholesterolemia	3
Adipose Tissue, Brown	1
Non-ST Segment Elevation Myocardial Infarction	1
Atherosclerosis	1

Condition MeSH

Condition MeSH for LESCOL XL
Intervention	Trials
Hypercholesterolemia	3
Coronary Disease	2
Coronary Artery Disease	2
Myocardial Ischemia	2

Clinical Trial Locations for LESCOL XL

Trials by Country

Trials by Country for LESCOL XL
Location	Trials
United States	37
China	2
Switzerland	2
Italy	1
Austria	1

Trials by US State

Trials by US State for LESCOL XL
Location	Trials
California	2
Oklahoma	2
Massachusetts	2
Georgia	1
Florida	1

Clinical Trial Progress for LESCOL XL

Clinical Trial Phase

Clinical Trial Phase for LESCOL XL
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for LESCOL XL
Clinical Trial Phase	Trials
Completed	7
Unknown status	2
Terminated	1

Clinical Trial Sponsors for LESCOL XL

Sponsor Name

Sponsor Name for LESCOL XL
Sponsor	Trials
Novartis	2
University Health Network, Toronto	1
University of Basel	1

Sponsor Type

Sponsor Type for LESCOL XL
Sponsor	Trials
Other	10
Industry	4
U.S. Fed	2